K. Cheng

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018, The Lancet. Oncology.

616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)

J. Tabernero, P. Hoff, J. Eng-Wong, 2017 .

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

E. Swisher, A. Cimino-Mathews, N. Gupta, 2022, Science Translational Medicine.

Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

P. Savas, A. Italiano, E. Espinosa, 2021 .

Abstract PD14-03: Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC)

P. Savas, A. Italiano, E. Espinosa, 2021 .

Contrast-Enhanced Liver Magnetic Resonance Image Synthesis Using Gradient Regularized Multi-Modal Multi-Discrimination Sparse Attention Fusion GAN

Changzhe Jiao, Wensha Yang, H. Thomas, 2023, Cancers.